Abstract
Background.: Several tests have been proposed for evaluating dyspeptic symptoms and their relationship to the underlying gastric disease. Serum pepsinogens and gastrin-17 are known to be useful biomarkers for the detection of gastric pathologies. Aim.: To evaluate the capability of screening dyspeptic patients in the primary care by analyses of serum pepsinogens I (sPGI) and II (sPGII), gastrin-17 (sG-17) and the IgG anti-Helicobacter pylori antibodies (IgG-Hp). Patients and methods.: Three hundred and sixty-two consecutive patients with dyspeptic symptoms (208 females, mean age 50.6 ± 16 years, range 18-88 years) referred by general practitioners for upper gastrointestinal endoscopy were enrolled. A blood sample was taken from each subject for IgG-Hp, sPGI, sPGII and sG-17 analyses. Results.: Two hundred and eighty-seven patients had a complete screening; of these, 132 resulted positive for Hp infection. Patients with atrophic chronic gastritis showed significantly lower serum pepsinogen I levels and sPGI/sPGII ratio than patients with non-atrophic chronic gastritis. Moreover, by calculating the values of sPGI by sG-17 and sG-17 by sPGII/sPGI, subjects with atrophic chronic gastritis could be distinguished from those with non-atrophic chronic gastritis and from those with normal mucosa, respectively. sG-17 levels were found to be a useful biomarker for the detection of antral atrophic gastritis, while the combination of sPGI, the sPGI/sPGII ratio and sG-17 was found effective in identifying corpus atrophy. Conclusion.: A panel composed of PGI, PGII, G-17 and IgG-Hp could be used as a first approach in the 'test and scope' and/or 'test and treat' strategy in the primary care management of dyspeptic patients.
| Original language | English |
|---|---|
| Pages (from-to) | 501-508 |
| Number of pages | 8 |
| Journal | Digestive and Liver Disease |
| Volume | 37 |
| Issue number | 7 |
| DOIs | |
| Publication status | Published - Jul 2005 |
Fingerprint
Keywords
- Chronic gastritis
- Dyspeptic patients
- Gastrin-17
- IgG anti-H. pylori
- Serum pepsinogens
ASJC Scopus subject areas
- Gastroenterology
Cite this
Clinical usefulness of serum pepsinogens I and II, gastrin-17 and anti-Helicobacter pylori antibodies in the management of dyspeptic patients in primary care. / Germaná, B.; Di Mario, F.; Cavallaro, L. G.; Moussa, A. M.; Lecis, P.; Liatoupolou, S.; Comparato, G.; Carloni, C.; Bertiato, G.; Battiestel, M.; Papa, N.; Aragona, G.; Cavestro, G. M.; Iori, V.; Merli, R.; Bertolini, S.; Caruana, P.; Franzé, A.
In: Digestive and Liver Disease, Vol. 37, No. 7, 07.2005, p. 501-508.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Clinical usefulness of serum pepsinogens I and II, gastrin-17 and anti-Helicobacter pylori antibodies in the management of dyspeptic patients in primary care
AU - Germaná, B.
AU - Di Mario, F.
AU - Cavallaro, L. G.
AU - Moussa, A. M.
AU - Lecis, P.
AU - Liatoupolou, S.
AU - Comparato, G.
AU - Carloni, C.
AU - Bertiato, G.
AU - Battiestel, M.
AU - Papa, N.
AU - Aragona, G.
AU - Cavestro, G. M.
AU - Iori, V.
AU - Merli, R.
AU - Bertolini, S.
AU - Caruana, P.
AU - Franzé, A.
PY - 2005/7
Y1 - 2005/7
N2 - Background.: Several tests have been proposed for evaluating dyspeptic symptoms and their relationship to the underlying gastric disease. Serum pepsinogens and gastrin-17 are known to be useful biomarkers for the detection of gastric pathologies. Aim.: To evaluate the capability of screening dyspeptic patients in the primary care by analyses of serum pepsinogens I (sPGI) and II (sPGII), gastrin-17 (sG-17) and the IgG anti-Helicobacter pylori antibodies (IgG-Hp). Patients and methods.: Three hundred and sixty-two consecutive patients with dyspeptic symptoms (208 females, mean age 50.6 ± 16 years, range 18-88 years) referred by general practitioners for upper gastrointestinal endoscopy were enrolled. A blood sample was taken from each subject for IgG-Hp, sPGI, sPGII and sG-17 analyses. Results.: Two hundred and eighty-seven patients had a complete screening; of these, 132 resulted positive for Hp infection. Patients with atrophic chronic gastritis showed significantly lower serum pepsinogen I levels and sPGI/sPGII ratio than patients with non-atrophic chronic gastritis. Moreover, by calculating the values of sPGI by sG-17 and sG-17 by sPGII/sPGI, subjects with atrophic chronic gastritis could be distinguished from those with non-atrophic chronic gastritis and from those with normal mucosa, respectively. sG-17 levels were found to be a useful biomarker for the detection of antral atrophic gastritis, while the combination of sPGI, the sPGI/sPGII ratio and sG-17 was found effective in identifying corpus atrophy. Conclusion.: A panel composed of PGI, PGII, G-17 and IgG-Hp could be used as a first approach in the 'test and scope' and/or 'test and treat' strategy in the primary care management of dyspeptic patients.
AB - Background.: Several tests have been proposed for evaluating dyspeptic symptoms and their relationship to the underlying gastric disease. Serum pepsinogens and gastrin-17 are known to be useful biomarkers for the detection of gastric pathologies. Aim.: To evaluate the capability of screening dyspeptic patients in the primary care by analyses of serum pepsinogens I (sPGI) and II (sPGII), gastrin-17 (sG-17) and the IgG anti-Helicobacter pylori antibodies (IgG-Hp). Patients and methods.: Three hundred and sixty-two consecutive patients with dyspeptic symptoms (208 females, mean age 50.6 ± 16 years, range 18-88 years) referred by general practitioners for upper gastrointestinal endoscopy were enrolled. A blood sample was taken from each subject for IgG-Hp, sPGI, sPGII and sG-17 analyses. Results.: Two hundred and eighty-seven patients had a complete screening; of these, 132 resulted positive for Hp infection. Patients with atrophic chronic gastritis showed significantly lower serum pepsinogen I levels and sPGI/sPGII ratio than patients with non-atrophic chronic gastritis. Moreover, by calculating the values of sPGI by sG-17 and sG-17 by sPGII/sPGI, subjects with atrophic chronic gastritis could be distinguished from those with non-atrophic chronic gastritis and from those with normal mucosa, respectively. sG-17 levels were found to be a useful biomarker for the detection of antral atrophic gastritis, while the combination of sPGI, the sPGI/sPGII ratio and sG-17 was found effective in identifying corpus atrophy. Conclusion.: A panel composed of PGI, PGII, G-17 and IgG-Hp could be used as a first approach in the 'test and scope' and/or 'test and treat' strategy in the primary care management of dyspeptic patients.
KW - Chronic gastritis
KW - Dyspeptic patients
KW - Gastrin-17
KW - IgG anti-H. pylori
KW - Serum pepsinogens
UR - http://www.scopus.com/inward/record.url?scp=26944468729&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=26944468729&partnerID=8YFLogxK
U2 - 10.1016/j.dld.2005.01.016
DO - 10.1016/j.dld.2005.01.016
M3 - Article
VL - 37
SP - 501
EP - 508
JO - Digestive and Liver Disease
JF - Digestive and Liver Disease
SN - 1590-8658
IS - 7
ER -